Ray Dalio Biogen Inc. Transaction History

Bridgewater Associates, LP

$17.3 Billion
Q3 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Biogen Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 72,104 shares of BIIB stock, worth $10.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

72,104

Previous 16,416 339.23%

Holding current value

$10.7 Million

Previous $3.81 Million 267.31%

% of portfolio

0.08%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$189.07 - $236.8 $10.5 Million - $13.2 Million	55,688 Added 339.23%	72,104 $14 Million
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $5.44 Million - $6.76 Million	-28,536 Reduced 63.48%	16,416 $3.81 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $20.8 Million - $26.3 Million	-98,334 Reduced 68.63%	44,952 $9.69 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $1.69 Million - $2.03 Million	-7,591 Reduced 5.03%	143,286 $37.1 Million
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $6.2 Million - $6.99 Million	24,458 Added 19.35%	150,877 $38.8 Million
Q2 2023 Aug 11, 2023	SELL	$275.25 - $318.06 $5.86 Million - $6.78 Million	-21,306 Reduced 14.42%	126,419 $36 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $9.47 Million - $10.8 Million	36,928 Added 33.33%	147,725 $41.1 Million
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $713,395 - $866,790	-2,826 Reduced 2.49%	110,797 $30.7 Million
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $30 Million - $41.4 Million	-154,308 Reduced 57.59%	113,623 $30.3 Million
Q2 2022 Aug 11, 2022	BUY	$187.54 - $223.02 $43.2 Million - $51.4 Million	230,412 Added 614.12%	267,931 $54.6 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $4.87 Million - $6.13 Million	25,115 Added 202.48%	37,519 $7.9 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $48,814 - $62,733	-218 Reduced 1.73%	12,404 $2.98 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $1.48 Million - $1.93 Million	-5,234 Reduced 29.31%	12,622 $3.57 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $2.45 Million - $3.92 Million	9,459 Added 112.65%	17,856 $6.18 Million
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $2.04 Million - $2.39 Million	8,397 New	8,397 $2.35 Million
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $52.3 Million - $72.2 Million	-237,455 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $2.5 Million - $2.8 Million	-11,478 Reduced 4.61%	237,455 $55.3 Million
Q2 2019 Aug 13, 2019	BUY	$219.29 - $241.72 $1.88 Million - $2.07 Million	8,555 Added 3.56%	248,933 $58.2 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $42.1 Million - $65.9 Million	194,483 Added 423.76%	240,378 $56.8 Million
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $7.09 Million - $8.98 Million	25,463 Added 124.62%	45,895 $13.8 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $700,608 - $916,202	-2,387 Reduced 10.46%	20,432 $7.22 Million
Q2 2018 Aug 13, 2018	SELL	$257.52 - $306.91 $14 Million - $16.7 Million	-54,378 Reduced 70.44%	22,819 $0
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $20.1 Million - $28.4 Million	77,197 New	77,197 $21.1 Million
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $13.6 Million - $15.2 Million	-44,198 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $12.4 Million - $14.6 Million	44,198	44,198 $13.8 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account